Characterization of Fecal Microbiota in a Population Aged 50 to 75 Years Targeted by Seasonal Vaccination

Bioaster60 enrolled

Overview

The goal of this interventional study is to constitute a biological samples collection collected from healthy elderly volunteers and used for scientific purposes. The main questions it aims to answer are: * Improving knowledge of the composition of the gut microbiota * Identify, isolate and culture microbiota species of interest in the field of health ageing or used as therapeutics associated to the vaccination * Determining the correlation between the gut microbiota composition and the immune response of individuals.

The compositional analysis of commensal bacterial populations collected from a variety of clinical samples has been recently made possible with the availability of Next Generation Sequencing (NGS) technologies. The term 'next-generation probiotics' (NGP) is now widely used to describe these commensal species of potential health interest. However, this approach is still hampered by the fact that there are usually few or even no strains available for a number of commensal species. In this context, BIOASTER has developed a specific technological process based on flow cytometry analysis and then sorting under strictly anaerobic conditions to target and cultivate commensal species of interest. The goal of this study is to constitute a biological samples collection from elderly people, to proceed with the isolation of beneficial commensal strains such as Faecalibacterium prausnitzii, Akkermansia muciniphila and Oscillospiraceae, in a non-limitative way. BIOASTER's objective is to strengthen technological support, provide new knowledges and tools for the development of next-generation products. Numerous biotherapeutics companies will benefit from this pipeline, ultimately improving the chances of survival in life-threatening diseases with unmet medical needs. Elderly people will be recruited by the investigational unit Biofortis. Blood (Whole blood + TruCulture tubes) and feces will be collected from each volunteer.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Conditions

Elderly Volunteers

Interventions

Biological samples collection (blood + feces)OTHER

Blood + stools samples will be collected from each volunteer

Eligibility

Sex: ALLMin age: 50 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects aged between 50 and 75, * BMI between 18.5 and 29 kg/m2, * Normal clinical examination, * Written consent obtained Exclusion Criteria: * Diagnosed acute or chronic gastrointestinal disease or complication (e.g., celiac disease, gastroesophageal reflux, gastric or duodenal ulcer, Crohn's disease, hemorrhoids, irritable bowel syndrome) * Infectious gastrointestinal event within 3 months prior to inclusion * Severe chronic disease (active cancer, HIV, severe renal failure, ongoing severe heart or liver or biliary disorders, arthritis) or severe chronic disease deemed incompatible with the conduct of the study by the investigator * Major surgical procedure likely to disrupt the intestinal microbiota, within 6 months prior to inclusion * Recent food allergy \< 3 months prior to inclusion * Antibiotic, antiviral, antifungal, proton pump inhibitor or any other treatment likely to disrupt the microbiota in the 3 months prior to inclusion * Previous or current use of a treatment that may disrupt the microbiota (e.g. laxatives, antidiarrheals, antacids...) in the last 3 months * Significant change in dietary habits or physical activities in the 3 months prior to inclusion * Consumption of more than 2 standard glasses of alcoholic beverages per day * Smoking \> 20 cigarettes per day, illicit drug use, * Daily use of non-steroidal anti-inflammatory drugs (NSAIDs) * Severe psychiatric or neurological pathology * Subject with liquid stools (Bristol Score = 7) or very hard stools (Bristol Score = 1) * Any vaccination in the last month before inclusion * Subject unable to understand the purpose of the research, answer questions and give their decision to participate in the study * Subject already included in another research study involving the human subject * Subject under guardianship and whose guardianship objects to the participation of his/her protectee, * Subject not affiliated with a social security plan or not a beneficiary of such a plan

Locations (1)

Biofortis

Paris, France

Outcomes

Primary Outcomes

Number and ratio of participants with per protocol collection of blood and feces

Number of volunteers included in the study and number blood/feces pairs collected.

Time frame: Baseline

Total number of bacteria strains collected

Isolation and culture of bacteria of interest in anaerobic conditions: constitution of a biobank of Akkermansia muciniphila, Faecalibacterium prausnitzii and Oscillospiraceae) for research purposes.

Time frame: Baseline

Fecal microbiome richness as assessed by alpha diversity

Genus and species of bacteria contained in the intestinal microbiota (alpha diversity calculation)

Time frame: Baseline

Secondary Outcomes

Immunophenotyping of volunteers as assessed by cytokines quantification

serum samples will be analyzed by ELISA method to quantify cytokines

Time frame: Baseline

Immunophenotyping of volunteers as assessed by flow cytometry on immune cells

peripheral blood mononuclear cells will be stained with specific markers antibodies to characterize immune cells populations

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.